NASDAQ · DNLI
Denali Therapeutics Inc.
$19.04-$0.28 (-1.45%)
Denali Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.26% below the high.
Loading market information…
NASDAQ · SVA · USD
Stock price, earnings
Quote as of Feb 11, 2025, 05:18 AM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sinovac Biotech Ltd.’s next earnings report is currently expected on May 3, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sinovac Biotech Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sinovac Biotech Ltd. is a biopharmaceutical firm primarily dedicated to the discovery, research, manufacturing, and sales of vaccines aimed at combating infectious human diseases across the People's Republic of China. Its extensive product range encompasses immunizations against Hepatitis A and B; hand, foot, and mouth disease caused by Enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza strains; coronavirus; varicella (chickenpox); and mumps. Among its commercially available vaccines are Healive, an inactivated Hepatitis A vaccine; Bilive, offering combined inactivated protection for Hepatitis A and B; Anflu, a split-virion influenza vaccine; Panflu, targeting the H5N1 influenza virus; Panflu.1, for the influenza A H1N1 virus; a mumps vaccine; another split-virion pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company further supplies a varicella vaccine; a pneumococcal polysaccharide vaccine designed to prevent Streptococcus pneumoniae infections like pneumonia and septicemia; a quadrivalent influenza vaccine providing defense against two influenza A and two influenza B viruses; and CoronaVac, its vaccine developed to address COVID-19. Additionally, Sinovac's development pipeline features a sabin inactivated polio vaccine, which has concluded Phase III clinical trials for poliomyelitis treatment, alongside a rubella vaccine candidate. The company has established several collaboration agreements, including with GlaxoSmithKline Biologicals SA for the development of measles-containing combination vaccines for the Chinese market; with Tianjin CanSino Biotechnology Inc. to advance a pneumococcal vaccine; and with Instituto Butantan to progress the Phase III clinical trials of CoronaVac, its inactivated COVID-19 vaccine candidate. Sinovac Biotech Ltd. was established in 1993 and maintains its principal offices in Beijing, China.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:36 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $33.82 |
| $8.39B |
| Q2 2021 | Oct 1, 2021 | -$0.05 | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$19.04-$0.28 (-1.45%)
Denali Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.26% below the high.
$29.60-$0.29 (-0.98%)
Celldex Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.43% below the high.
$34.67+$0.42 (+1.23%)
Sonida Senior Living, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.9% below the high.
$22.55-$0.71 (-3.05%)
China Yuchai International Limited’s quoted price sits in the lower half of its reported 52-week range, 63.32% below the high.
$2.24-$0.06 (-2.4%)
CytomX Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.78% below the high.
$4.33+$0.01 (+0.2%)
China Automotive Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 23.25% below the high.
$0.77+$0.02 (+2.64%)
Origin Agritech Limited’s quoted price sits in the lower half of its reported 52-week range, 56.99% below the high.
$24.42-$0.47 (-1.89%)
FIS Tactical Equity ETF’s quoted price sits in the lower half of its reported 52-week range, 16.88% below the high.
